fingolimod hydrochloride has been researched along with Brain Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Brunetto, AL; Brunetto, AT; da Cunha Jaeger, M; da Silveira Perla, A; Dalmolin, MGS; de Farias, CB; Fratini, L; Roesler, R; Sinigaglia, M | 1 |
| Doello, K; Mesas, C; Ortiz, R; Perazzoli, G; Quiñonero, F; Rama, AR; Vélez, C | 1 |
| Liu, L; Ma, M; Wu, H; Zhang, Y | 1 |
| Cambron, B; Delrée, P; Gustin, T; Jacobs, S; London, F | 1 |
| Al Barim, B; Di Fazio, P; Kolodziej, MA; Nagl, J; Schwarm, FP; Stein, M; Uhl, E; Uhle, F; Weigand, MA | 1 |
| Alassiri, A; Algahtani, H; Shirah, B | 1 |
| Banu, MA; Berry, N; Boockvar, JA; Clausi, MG; Ryu, S; Stessin, AM | 1 |
| Wang, H; Zhang, L | 1 |
| Alessandri, G; Bornati, A; Campanella, R; de Rezende, G; Di Vito, C; Giussani, P; Hadi, LA; Marfia, G; Navone, SE; Parati, E; Rampini, P; Riboni, L; Riccitelli, E; Tringali, C; Viani, P | 1 |
| Golzy, N; Pouratian, N; Sharim, J; Tashjian, R | 1 |
| Estrada-Bernal, A; Palanichamy, K; Ray Chaudhury, A; Van Brocklyn, JR | 1 |
1 review(s) available for fingolimod hydrochloride and Brain Neoplasms
| Article | Year |
|---|---|
Tumefactive demyelinating lesions: A comprehensive review.
Topics: Adrenal Cortex Hormones; Brain Neoplasms; Central Nervous System Neoplasms; Demyelinating Autoimmune Diseases, CNS; Deprescriptions; Diagnosis, Differential; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Natalizumab; Plasma Exchange; Risk Factors | 2017 |
10 other study(ies) available for fingolimod hydrochloride and Brain Neoplasms
| Article | Year |
|---|---|
ZEB1 is a Subgroup-Specific Marker of Prognosis and Potential Drug Target in Medulloblastoma.
Topics: Adolescent; Brain Neoplasms; Cerebellar Neoplasms; Cerebellum; Child; Fingolimod Hydrochloride; Histone Deacetylase Inhibitors; Humans; Medulloblastoma; Zinc Finger E-box-Binding Homeobox 1 | 2023 |
Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.
Topics: Adult; Apoptosis; Biperiden; Brain Neoplasms; Cell Line, Tumor; Dextromethorphan; Fingolimod Hydrochloride; Glioblastoma; Haloperidol; Humans; Levetiracetam; Methotrimeprazine; Valproic Acid | 2022 |
Modulation of blood-brain tumor barrier for delivery of magnetic hyperthermia to brain cancer.
Topics: Blood-Brain Barrier; Brain Neoplasms; Endothelial Cells; Fingolimod Hydrochloride; Glioblastoma; Humans; Hyperthermia, Induced; Magnetic Phenomena | 2023 |
Glioblastoma in a fingolimod-treated multiple sclerosis patient: Causal or coincidental association?
Topics: Brain; Brain Neoplasms; Female; Fingolimod Hydrochloride; Glioblastoma; Humans; Middle Aged; Multiple Sclerosis; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
Sphingosine‑1‑phosphate analogue FTY720 exhibits a potent anti‑proliferative effect on glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Fingolimod Hydrochloride; Glioblastoma; Humans; rho-Associated Kinases; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Temozolomide | 2020 |
FTY720/fingolimod, an oral S1PR modulator, mitigates radiation induced cognitive deficits.
Topics: Animals; Brain Neoplasms; Cognition; Cognitive Dysfunction; Fingolimod Hydrochloride; Hippocampus; Mice, Inbred C57BL; Neural Stem Cells; Neurogenesis; Radiation Injuries; Radiotherapy; Receptors, Lysosphingolipid | 2017 |
FTY720 inhibits the Nrf2/ARE pathway in human glioblastoma cell lines and sensitizes glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antioxidant Response Elements; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Gene Knockdown Techniques; Glioblastoma; Heme Oxygenase-1; Humans; NF-E2-Related Factor 2; RNA, Messenger; RNA, Small Interfering; Temozolomide | 2017 |
Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Cells, Cultured; Ceramides; Epidermal Growth Factor; Extracellular Fluid; Fibroblast Growth Factor 2; Fingolimod Hydrochloride; Glioblastoma; Humans; Immunosuppressive Agents; Ki-67 Antigen; Lysophospholipids; Mice; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Propylene Glycols; Sphingolipids; Sphingosine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
Topics: Brain Neoplasms; Female; Fingolimod Hydrochloride; Glioblastoma; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2016 |
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Dacarbazine; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Glioblastoma; Humans; Induction Chemotherapy; Membrane Proteins; Mice; Mice, Nude; Neoplastic Stem Cells; Propylene Glycols; Proto-Oncogene Proteins; Receptors, Lysosphingolipid; Sphingosine; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |